167 related articles for article (PubMed ID: 29718270)
1. Protein adhesins as vaccine antigens for Group A Streptococcus.
Raynes JM; Young PG; Proft T; Williamson DA; Baker EN; Moreland NJ
Pathog Dis; 2018 Mar; 76(2):. PubMed ID: 29718270
[TBL] [Abstract][Full Text] [Related]
2. Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model.
McArthur J; Medina E; Mueller A; Chin J; Currie BJ; Sriprakash KS; Talay SR; Chhatwal GS; Walker MJ
Infect Immun; 2004 Dec; 72(12):7342-5. PubMed ID: 15557665
[TBL] [Abstract][Full Text] [Related]
3. Group A streptococcal vaccines: facts versus fantasy.
Steer AC; Batzloff MR; Mulholland K; Carapetis JR
Curr Opin Infect Dis; 2009 Dec; 22(6):544-52. PubMed ID: 19797947
[TBL] [Abstract][Full Text] [Related]
4. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.
Good MF; Pandey M; Batzloff MR; Tyrrell GJ
Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214
[TBL] [Abstract][Full Text] [Related]
5. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.
Tsoi SK; Smeesters PR; Frost HR; Licciardi P; Steer AC
J Immunol Res; 2015; 2015():167089. PubMed ID: 26101780
[TBL] [Abstract][Full Text] [Related]
6. Immunization with a streptococcal multiple-epitope recombinant protein protects mice against invasive group A streptococcal infection.
Kuo CF; Tsao N; Hsieh IC; Lin YS; Wu JJ; Hung YT
PLoS One; 2017; 12(3):e0174464. PubMed ID: 28355251
[TBL] [Abstract][Full Text] [Related]
7. Development of Group A streptococcal vaccines: an unmet global health need.
Sheel M; Moreland NJ; Fraser JD; Carapetis J
Expert Rev Vaccines; 2016; 15(2):227-38. PubMed ID: 26559880
[TBL] [Abstract][Full Text] [Related]
8. Identification and assessment of new vaccine candidates for group A streptococcal infections.
McMillan DJ; Batzloff MR; Browning CL; Davies MR; Good MF; Sriprakash KS; Janulczyk R; Rasmussen M
Vaccine; 2004 Jul; 22(21-22):2783-90. PubMed ID: 15246612
[TBL] [Abstract][Full Text] [Related]
9. Clinical development strategy for a candidate group A streptococcal vaccine.
Schödel F; Moreland NJ; Wittes JT; Mulholland K; Frazer I; Steer AC; Fraser JD; Carapetis J
Vaccine; 2017 Apr; 35(16):2007-2014. PubMed ID: 28318768
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.
Kotloff KL; Corretti M; Palmer K; Campbell JD; Reddish MA; Hu MC; Wasserman SS; Dale JB
JAMA; 2004 Aug; 292(6):709-15. PubMed ID: 15304468
[TBL] [Abstract][Full Text] [Related]
11. Strategies in the development of vaccines to prevent infections with group A streptococcus.
Good MF; Batzloff MR; Pandey M
Hum Vaccin Immunother; 2013 Nov; 9(11):2393-7. PubMed ID: 23863455
[TBL] [Abstract][Full Text] [Related]
12. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
13. A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes.
Bi S; Xu M; Zhou Y; Xing X; Shen A; Wang B
mBio; 2019 Nov; 10(6):. PubMed ID: 31772056
[TBL] [Abstract][Full Text] [Related]
14. [Recombinant fragments of conservative proteins of group B streptococci as a basis of specific vaccine].
Suvorov AN; Grabovskaia KB; Leont'eva GF; Meringova LF; Koroleva IN; Duplik NV; Totolian AA
Zh Mikrobiol Epidemiol Immunobiol; 2010; (2):44-50. PubMed ID: 20465000
[TBL] [Abstract][Full Text] [Related]
15. Current status of group A streptococcal vaccine development.
Dale JB
Adv Exp Med Biol; 2008; 609():53-63. PubMed ID: 18193657
[TBL] [Abstract][Full Text] [Related]
16. Molecular biology of Group A
Brahmadathan NK
Indian J Med Microbiol; 2017; 35(2):176-183. PubMed ID: 28681803
[TBL] [Abstract][Full Text] [Related]
17. Systemic immunization with streptococcal immunoglobulin-binding protein Sib 35 induces protective immunity against group: a Streptococcus challenge in mice.
Okamoto S; Tamura Y; Terao Y; Hamada S; Kawabata S
Vaccine; 2005 Sep; 23(40):4852-9. PubMed ID: 15990202
[TBL] [Abstract][Full Text] [Related]
18. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain.
Schulze K; Medina E; Guzmán CA
Vaccine; 2006 Feb; 24(9):1446-50. PubMed ID: 16289766
[TBL] [Abstract][Full Text] [Related]
19. Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.
Batzloff MR; Fane A; Gorton D; Pandey M; Rivera-Hernandez T; Calcutt A; Yeung G; Hartas J; Johnson L; Rush CM; McCarthy J; Ketheesan N; Good MF
Hum Vaccin Immunother; 2016 Dec; 12(12):3089-3096. PubMed ID: 27541593
[TBL] [Abstract][Full Text] [Related]
20. Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.
Chuan YP; Wibowo N; Connors NK; Wu Y; Hughes FK; Batzloff MR; Lua LH; Middelberg AP
Biotechnol Bioeng; 2014 Jun; 111(6):1062-70. PubMed ID: 24338691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]